Skip to content

Study · Animal study (in vivo) · rat · 2013

6 results

Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy.

Cesarec V, Becejac T, Misic M, Djakovic Z, Olujic D, Drmic D, Brcic L, Rokotov DS, Seiwerth S, Sikiric P

European journal of pharmacology7 Dec 2012Cited by 44 (Europe PMC)

PMID23220707 (opens in a new tab)DOI10.1016/j.ejphar.2012.11.055 (opens in a new tab)PepBankPUB-23220707
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with esophagocutaneous fistulas, BPC‑157 accelerated fistula healing and completely counteracted the effects of L-NAME.

    In plain wordsIn rats with a gullet-to-skin fistula, BPC‑157 sped up healing and fully countered the harm from L-NAME.

    Peptide
    BPC-157
    Outcome
    IncreaseFistula healing course
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    the course of fistula healing was accelerated either to a greater extent (with BPC 157 (in particular, less eNOS gene expression) completely counteracting L-NAME effects
    1 context sentence
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In rats with esophagocutaneous fistulas, BPC‑157 gave less eNOS gene expression.

    In plain wordsIn rats with a gullet-to-skin fistula, BPC‑157 lowered activity of the eNOS gene.

    Peptide
    BPC-157
    Outcome
    DecreaseeNOS gene expression in fistulas
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    in particular, less eNOS gene expression) completely counteracting L-NAME effects, in L-NAME+BPC 157 and L-NAME+l-arginine+BPC 157 groups), or to a lesser extent (with l-arginine).
    1 context sentence
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with esophagocutaneous fistulas, defects started to heal with less fistula leakage.

    In plain wordsIn rats with a gullet-to-skin fistula, defects began to heal and leaked less.

    Peptide
    BPC-157
    Outcome
    DecreaseFistula leakage
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    Shortly, defects started to heal, with less fistula leakage and no mortality at day 4.
    1 context sentence
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with esophagocutaneous fistulas, no animals died by day 4, although the fistulas are usually lethal.

    In plain wordsIn rats with a gullet-to-skin fistula, none died by day 4, although such fistulas are usually lethal.

    Peptide
    BPC-157
    Outcome
    DecreaseMortality at day 4
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Mortality · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    Shortly, defects started to heal, with less fistula leakage and no mortality at day 4.
    2 context sentences
    Summary · context
    usually lethal, particularly NO-system related and therapy dependent.
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with esophagocutaneous fistulas, failure of pyloric and lower esophageal sphincter pressure was restored.

    In plain wordsIn rats with a gullet-to-skin fistula, the lost pressure in the stomach outlet and lower gullet valves was restored.

    Peptide
    BPC-157
    Outcome
    IncreasePyloric and lower esophageal sphincter pressure
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    Failure of pyloric and lower esophageal sphincter pressure was restored
    1 context sentence
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with esophagocutaneous fistulas, there was practically no esophagitis.

    In plain wordsIn rats with a gullet-to-skin fistula, there was almost no inflammation of the gullet.

    Peptide
    BPC-157
    Outcome
    DecreaseEsophagitis
    Study

    ratn: not reported in source

    Cervical esophagocutaneous fistula
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    µg- and ng-regimens · parenteral and per-oral · 4 daysAs given in this study (rat).

    Source sentences

    Summary
    with practically no esophagitis.
    1 context sentence
    Summary · context
    We treated rats with established cervical esophagocutaneous fistulas throughout four days (both open skin and esophageal defects, with significant leakage) with BPC 157 (parenterally and perorally) and L-NAME (blocking NO genesis) and l-arginine (NO-substrate) alone or in combination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.